SARS-CoV-2中和抗体的半定量高通量分析:感染/接种后免疫反应抗体水平及持续时间测量
本研究基于cPass替代病毒中和试验(sVNT)建立自动化高通量工作流,用于定量检测SARS-CoV-2中和抗体,并评估样本冻融与冷藏稳定性。疫苗接种前后样本显示首剂后中和抗体不可测或较低,第二剂后数月内水平纵向下降。
要点
- cPass sVNT可在自动化液体处理平台上实现高通量半定量检测中和抗体。
- 感染/康复者中和抗体反应差异可达600倍,约半数样本滴度较低。
- 疫苗首剂后中和抗体不可测或较低,第二剂后数月内水平下降。
核心结论
- 自然感染与疫苗接种后的中和(阻断)抗体呈宽范围差异,支持存在差异化免疫应答。
- 接种后检测SARS-CoV-2中和抗体滴度可能有助于评估免疫保护的强度与持久性。
研究设计与样本
- 方法学研究:在Tecan EVO与Dynex Agility平台上建立cPass sVNT自动化高通量工作流。
- 评估样本在冻融与冷藏储存条件下SARS-CoV-2中和抗体的稳定性。
- 检测疫苗接种前后样本的中和抗体,采用定性及半定量cPass sVNT方案。
主要发现
- 疫苗首剂后中和抗体不可测或水平相对较低。
- 第二剂后数月内中和抗体水平纵向下降。
关键数值与推荐
- cPass sVNT为双重应用检测:SARS-CoV-2人群血清流行率监测,以及检测阻断RBD与宿主ACE2受体结合的中和抗体。
临床怎么用
- 可采用cPass sVNT在自动化平台上高通量半定量检测SARS-CoV-2中和抗体。
- 接种后监测中和抗体滴度可辅助评估免疫保护强度与持久性。
- 样本冻融与冷藏储存条件下的中和抗体稳定性信息可用于实验室样本管理。
局限性
- 原文未报告样本冻融与冷藏稳定性比较的具体数值结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The question associated with efficacy and longevity of SARS-CoV-2 protection post-vaccination is paramount. The cPass surrogate virus neutralization test (sVNT) has gained popularity globally as a dual application assay for: 1. Accurate SARS-CoV-2 population surveillance (seroprevalence) analysis and 2. Revealing the presence of antibodies that block and effectively neutralize the interaction between the SARS-CoV-2 receptor binding domain and the host cell ACE2 receptor in recovered or vaccinated individuals. This study describes an approach for accurate quantification of neutralizing antibodies using the cPass sVNT with an automated workflow on the Tecan EVO and Dynex Agility platforms that is applicable to other liquid handling systems. This methodology was used to assess the stability of SARS-CoV-2 neutralizing antibodies between freeze/thaw and refrigerated sample storage conditions. Furthermore, a subset of twenty-five samples from SARS-CoV-2 infected/recovered individuals revealed a 600-fold difference in the neutralizing antibody response where low titers were represented in about half of the samples. Finally, pre- and post-vaccination samples were tested for neutralizing antibodies using the qualitative and semi-quantitative cPass sVNT protocols revealing undetectable or relatively low levels after the first vaccine dose and a decline in levels longitudinally over the months following the second dose. This wide range in neutralizing (blocking) antibodies from both natural infection and vaccination supports a differential immune response that may be attributed to several physiological and genetic factors underlining the potential for measuring SARS-CoV-2 neutralizing antibody titer levels post-vaccination to help ensure robust and prolonged immunity.
引用
- Taylor SC, Hurst B, Martiszus I, et al. Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination. Vaccine. 2021. PMID: 34426026. doi:10.1016/j.vaccine.2021.07.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。